EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00339118 |
Recruitment Status : Unknown
Verified June 2006 by Sheba Medical Center.
Recruitment status was: Not yet recruiting
First Posted : June 20, 2006
Last Update Posted : June 20, 2006
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rhabdomyosarcoma | Drug: doxorubicin, cytoxan | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
- event free survival
- overall survival
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- child
- non metastatic rhabdomyosarcoma
- adequate heart, kidney, liver function
Exclusion Criteria:
- age over 21 years, under 6 months
- metastatic disease
- heart, kidney, liver disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00339118
Contact: Iris Kventsel, MD | 97235303037 | iris.kventsel@sheba.health.gov.il |
Principal Investigator: | Iris Kventsel, MD | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00339118 |
Other Study ID Numbers: |
SHEBA-06-4013-IK-CTIL |
First Posted: | June 20, 2006 Key Record Dates |
Last Update Posted: | June 20, 2006 |
Last Verified: | June 2006 |
Rhabdomyosarcoma Myosarcoma Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Sarcoma Doxorubicin Cyclophosphamide Antibiotics, Antineoplastic Antineoplastic Agents |
Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Myeloablative Agonists |